The association between circulating MicroRNA‐150 level and cholangiocarcinoma
Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19‐9 (CA19‐9) is currently the most commonly used tumor marker for CCA; nevertheless, it has certain limitations which need to be considered when using it as a tumor marker. MiRNA...
Saved in:
| Published in | Journal of clinical laboratory analysis Vol. 34; no. 11; pp. e23397 - n/a |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.11.2020
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0887-8013 1098-2825 1098-2825 |
| DOI | 10.1002/jcla.23397 |
Cover
| Abstract | Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19‐9 (CA19‐9) is currently the most commonly used tumor marker for CCA; nevertheless, it has certain limitations which need to be considered when using it as a tumor marker. MiRNA‐150 altered expression has been linked to the development and tumorigenesis of several cancers including CCA. This work aimed to study the serum level of CA19‐9 and miRNA‐150 expression in CCA patients and, also, to correlate their levels with tumor staging and different studied clinical and laboratory parameters. This work included 35 patients with CCA who were admitted to Hepatobiliary Unit, Alexandria Main University Hospital (Group I). Also, 35 age‐ and sex‐matched healthy subjects were included as a control group (Group II). All included subjects were submitted to measurement of serum CA19‐9 and MiRNA‐150 expression levels. Serum CA19‐9 levels showed an evident high median among CCA patients, while serum miRNA‐150 expression levels were evidently low among those patients. Moreover, combining miRNA‐150 with CA19‐9 made the accuracy of diagnosis of CCA much more reliable. Thus, miRNA‐150 can be considered as a non‐invasive, sensitive serum biomarker for the diagnosis of CCA especially when combined with CA 19‐9. |
|---|---|
| AbstractList | Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19‐9 (CA19‐9) is currently the most commonly used tumor marker for CCA; nevertheless, it has certain limitations which need to be considered when using it as a tumor marker. MiRNA‐150 altered expression has been linked to the development and tumorigenesis of several cancers including CCA. This work aimed to study the serum level of CA19‐9 and miRNA‐150 expression in CCA patients and, also, to correlate their levels with tumor staging and different studied clinical and laboratory parameters. This work included 35 patients with CCA who were admitted to Hepatobiliary Unit, Alexandria Main University Hospital (Group I). Also, 35 age‐ and sex‐matched healthy subjects were included as a control group (Group II). All included subjects were submitted to measurement of serum CA19‐9 and MiRNA‐150 expression levels. Serum CA19‐9 levels showed an evident high median among CCA patients, while serum miRNA‐150 expression levels were evidently low among those patients. Moreover, combining miRNA‐150 with CA19‐9 made the accuracy of diagnosis of CCA much more reliable. Thus, miRNA‐150 can be considered as a non‐invasive, sensitive serum biomarker for the diagnosis of CCA especially when combined with CA 19‐9. Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19-9 (CA19-9) is currently the most commonly used tumor marker for CCA; nevertheless, it has certain limitations which need to be considered when using it as a tumor marker. MiRNA-150 altered expression has been linked to the development and tumorigenesis of several cancers including CCA. This work aimed to study the serum level of CA19-9 and miRNA-150 expression in CCA patients and, also, to correlate their levels with tumor staging and different studied clinical and laboratory parameters. This work included 35 patients with CCA who were admitted to Hepatobiliary Unit, Alexandria Main University Hospital (Group I). Also, 35 age- and sex-matched healthy subjects were included as a control group (Group II). All included subjects were submitted to measurement of serum CA19-9 and MiRNA-150 expression levels. Serum CA19-9 levels showed an evident high median among CCA patients, while serum miRNA-150 expression levels were evidently low among those patients. Moreover, combining miRNA-150 with CA19-9 made the accuracy of diagnosis of CCA much more reliable. Thus, miRNA-150 can be considered as a non-invasive, sensitive serum biomarker for the diagnosis of CCA especially when combined with CA 19-9.Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19-9 (CA19-9) is currently the most commonly used tumor marker for CCA; nevertheless, it has certain limitations which need to be considered when using it as a tumor marker. MiRNA-150 altered expression has been linked to the development and tumorigenesis of several cancers including CCA. This work aimed to study the serum level of CA19-9 and miRNA-150 expression in CCA patients and, also, to correlate their levels with tumor staging and different studied clinical and laboratory parameters. This work included 35 patients with CCA who were admitted to Hepatobiliary Unit, Alexandria Main University Hospital (Group I). Also, 35 age- and sex-matched healthy subjects were included as a control group (Group II). All included subjects were submitted to measurement of serum CA19-9 and MiRNA-150 expression levels. Serum CA19-9 levels showed an evident high median among CCA patients, while serum miRNA-150 expression levels were evidently low among those patients. Moreover, combining miRNA-150 with CA19-9 made the accuracy of diagnosis of CCA much more reliable. Thus, miRNA-150 can be considered as a non-invasive, sensitive serum biomarker for the diagnosis of CCA especially when combined with CA 19-9. |
| Author | Ghazala, Rasha Abdelmawla Emara, Doaa Mokhtar Ahmed, Nesma Mahmoud Salem, Perihan El Sayed El Gendi, Ahmed Mohamed |
| AuthorAffiliation | 3 Department of Surgery Faculty of Medicine Alexandria University Alexandria Egypt 2 Medical Biochemistry Department Faculty of Medicine Alexandria University Alexandria Egypt 4 Department of Radiodiagnosis and Intervention Radiology Faculty of Medicine Alexandria University Alexandria Egypt 5 Internal Medicine Department Fever Hospital Alexandria University Alexandria Egypt 1 Internal Medicine Department Faculty of Medicine Alexandria University Alexandria Egypt |
| AuthorAffiliation_xml | – name: 5 Internal Medicine Department Fever Hospital Alexandria University Alexandria Egypt – name: 1 Internal Medicine Department Faculty of Medicine Alexandria University Alexandria Egypt – name: 2 Medical Biochemistry Department Faculty of Medicine Alexandria University Alexandria Egypt – name: 4 Department of Radiodiagnosis and Intervention Radiology Faculty of Medicine Alexandria University Alexandria Egypt – name: 3 Department of Surgery Faculty of Medicine Alexandria University Alexandria Egypt |
| Author_xml | – sequence: 1 givenname: Perihan El Sayed orcidid: 0000-0002-8383-4136 surname: Salem fullname: Salem, Perihan El Sayed email: drperihansalem@yahoo.com organization: Alexandria University – sequence: 2 givenname: Rasha Abdelmawla surname: Ghazala fullname: Ghazala, Rasha Abdelmawla organization: Alexandria University – sequence: 3 givenname: Ahmed Mohamed surname: El Gendi fullname: El Gendi, Ahmed Mohamed organization: Alexandria University – sequence: 4 givenname: Doaa Mokhtar surname: Emara fullname: Emara, Doaa Mokhtar organization: Alexandria University – sequence: 5 givenname: Nesma Mahmoud surname: Ahmed fullname: Ahmed, Nesma Mahmoud organization: Alexandria University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33161598$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1qGzEUhUVJaJy0mz5AGegmFCa9kkZ_m4Ix_QtOAyVdC41GtmVkKR3NJGTXR-gz9kkqx0loQ8lKIH3n6J57DtFeTNEh9ArDCQYg79Y2mBNCqRLP0ASDkjWRhO2hCUgpagmYHqDDnNcAIBXmz9EBpZhjpuQEnV-sXGVyTtabwadYtW64di5W1vd2DOUuLqszb_v07ev0989fmEEV3JULlYldZVcpmLj0yZre-pg25gXaX5iQ3cu78wh9__jhYva5np9_-jKbzmvLGiLqBTjSNm1nDZOSSGMdxtgRbsCSjgkhlVoI2xrLuWiopC1w1igQhnZYdhToEXq_870c243rrItDb4K-7P3G9Dc6Ga__fYl-pZfpSgsuOFa4GBzfGfTpx-jyoDc-WxdKHpfGrEnDpOIU5BZ98whdp7GPJZ4mHLhqMCXkSaopXzLKcFOo13_P_TDwfSMFgB1QVp5z7xba-uG2mhLDB41Bb0vX29L1belF8vaR5N71vzDewdc-uJsnSH06m093mj-lp7xC |
| CitedBy_id | crossref_primary_10_1016_j_prp_2023_154565 crossref_primary_10_2174_0115680266290367240130054142 crossref_primary_10_14701_ahbps_23_170 crossref_primary_10_7717_peerj_18367 crossref_primary_10_1021_acsomega_4c11078 crossref_primary_10_1016_j_lfs_2021_119626 crossref_primary_10_1002_1878_0261_13709 crossref_primary_10_1111_cas_15597 crossref_primary_10_3390_cancers14041026 crossref_primary_10_3389_fonc_2021_699401 crossref_primary_10_1097_MOG_0000000000000806 crossref_primary_10_2478_helm_2023_0036 crossref_primary_10_3389_fonc_2022_936507 crossref_primary_10_1016_j_prp_2023_154437 crossref_primary_10_1097_MOT_0000000000000983 crossref_primary_10_4251_wjgo_v13_i5_332 crossref_primary_10_3389_fonc_2021_768009 crossref_primary_10_3390_cancers13133222 crossref_primary_10_1002_cnr2_1964 crossref_primary_10_1097_CAD_0000000000001487 crossref_primary_10_3390_jmp3020009 crossref_primary_10_3390_cancers13133307 crossref_primary_10_1007_s11033_021_06450_6 crossref_primary_10_3390_ijms22147627 crossref_primary_10_1080_17474124_2021_1912591 |
| Cites_doi | 10.1055/s-2004-828891 10.1097/MOG.0b013e3282fbf9b3 10.1038/nrgastro.2011.131 10.1007/s10620-005-2927-8 10.1371/journal.pone.0080707 10.1136/gutjnl-2011-301122 10.1007/s13277-016-5313-6 10.1038/nrg2634 10.1517/14712590902932889 10.1074/jbc.M802663200 10.1186/1746-1596-8-158 10.1016/j.vph.2011.08.001 10.1002/hep.25890 10.1007/s00330-001-1188-y 10.1016/j.bbrc.2009.12.182 10.3892/ol.2015.3170 10.1002/hep.510310103 10.1371/journal.pone.0013515 10.1186/1471-2407-12-289 10.1097/01.ruq.0000263851.53549.a5 10.1055/s-2004-828892 10.1159/000128169 10.1016/j.cld.2007.11.003 10.1016/j.jhep.2008.09.015 10.1016/j.molonc.2012.09.006 10.1111/cas.12030 10.1046/j.1440-1746.2002.02779.x 10.3748/wjg.v10.i3.427 10.1016/j.bpg.2015.02.003 10.1111/j.1742-4658.2012.08618.x 10.1136/gut.51.suppl_6.vi1 10.4251/wjgo.v5.i7.132 10.3892/etm.2013.1311 10.1053/jlts.2000.18688 10.1016/j.ejca.2013.12.024 10.1093/carcin/bgr223 10.1038/ng.2007.30 10.3892/or.2014.3641 10.1016/j.cgh.2011.02.007 10.1016/j.cld.2010.03.011 10.1016/j.bpg.2015.02.001 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. Published by Wiley Periodicals LLC 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC. 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 The Authors. Published by Wiley Periodicals LLC – notice: 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC. – notice: 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 3V. 7QP 7T5 7U9 7X7 7XB 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1002/jcla.23397 |
| DatabaseName | Wiley Online Library Open Access (WRLC) CrossRef PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest - Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database Publicly Available Content Database PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access (WRLC) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | SALEM et al |
| EISSN | 1098-2825 |
| EndPage | n/a |
| ExternalDocumentID | PMC7676191 33161598 10_1002_jcla_23397 JCLA23397 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 6PF 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8C1 8FI 8FJ 8UM 930 A01 A03 A8Z AAESR AAEVG AAHHS AANHP AAONW AAWTL AAZKR ABCQN ABEML ABIJN ABPVW ABUWG ACBWZ ACCFJ ACCMX ACGFS ACMXC ACPRK ACRPL ACSCC ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADNMO ADPDF ADZMN AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFKRA AFPWT AFZJQ AHMBA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR ASPBG ATUGU AVUZU AVWKF AZBYB AZFZN AZVAB BAFTC BBNVY BCNDV BDRZF BENPR BFHJK BHBCM BHPHI BMXJE BROTX BRXPI BY8 CCPQU CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DU5 DUUFO EBD EBS EJD EMOBN F00 F01 F04 F1Z F5P FEDTE FUBAC FYUFA G-S G.N GNP GODZA GROUPED_DOAJ H.X HBH HCIFZ HF~ HHY HMCUK HVGLF HYE HZ~ IAO IHR ITC IX1 J0M JPC KQQ LAW LC2 LC3 LH4 LITHE LOXES LP6 LP7 LUTES LW6 M65 M7P MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PIMPY PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RPM RWI RX1 SAMSI SUPJJ SV3 TEORI TWZ UB1 UKHRP V2E W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XPP XV2 ~IA ~WT AAYXX AGQPQ CITATION PHGZM PHGZT AAMMB AEFGJ AGXDD AIDQK AIDYY NPM PJZUB PPXIY PQGLB 3V. 7QP 7T5 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQUKI PRINS 7X8 ESTFP PUEGO 5PM |
| ID | FETCH-LOGICAL-c5427-f0e2b4bdca58828ace111e26a0c2d577899f7cbac6674383b0654907a3d18d303 |
| IEDL.DBID | DR2 |
| ISSN | 0887-8013 1098-2825 |
| IngestDate | Thu Aug 21 18:29:27 EDT 2025 Mon Sep 08 17:50:54 EDT 2025 Wed Aug 13 03:56:53 EDT 2025 Wed Aug 13 06:32:07 EDT 2025 Mon Jul 21 05:43:51 EDT 2025 Tue Jul 01 02:27:44 EDT 2025 Thu Apr 24 22:51:14 EDT 2025 Wed Jan 22 16:33:05 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | serum CA19-9 risk factors for CCA diagnosis of CCA serum MiRNA-150 cholangiocarcinoma |
| Language | English |
| License | Attribution 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5427-f0e2b4bdca58828ace111e26a0c2d577899f7cbac6674383b0654907a3d18d303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-8383-4136 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcla.23397 |
| PMID | 33161598 |
| PQID | 2461953514 |
| PQPubID | 105667 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7676191 proquest_miscellaneous_2458963081 proquest_journals_2606941322 proquest_journals_2461953514 pubmed_primary_33161598 crossref_citationtrail_10_1002_jcla_23397 crossref_primary_10_1002_jcla_23397 wiley_primary_10_1002_jcla_23397_JCLA23397 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | November 2020 |
| PublicationDateYYYYMMDD | 2020-11-01 |
| PublicationDate_xml | – month: 11 year: 2020 text: November 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York – name: Hoboken |
| PublicationTitle | Journal of clinical laboratory analysis |
| PublicationTitleAlternate | J Clin Lab Anal |
| PublicationYear | 2020 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2012; 61 2002; 17 2010; 14 2011; 1 2000; 6 2002; 51 2002; 12 2013; 104 2015; 33 2004; 24 2015; 10 1999; 45 2011; 55 2008; 12 2011; 32 2013; 8 2012; 12 2012; 56 2013; 5 2016; 37 2013; 6 2011; 8 2008; 283 2011; 9 2002; 49 2004; 10 2009; 10 2015; 29 2009; 50 2000; 31 2008; 25 2009; 9 2008; 24 2010; 392 2005; 50 2012; 6 2012; 279 2008; 40 2014; 50 2010; 5 2007; 23 e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_36_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_35_1 e_1_2_11_12_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 Vestergaard EM (e_1_2_11_16_1) 1999; 45 e_1_2_11_2_1 Bragazzi MC (e_1_2_11_33_1) 2011; 1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_18_1 e_1_2_11_17_1 Chen CY (e_1_2_11_15_1) 2002; 49 e_1_2_11_37_1 e_1_2_11_38_1 e_1_2_11_39_1 e_1_2_11_19_1 |
| References_xml | – volume: 12 start-page: 131 issue: 1 year: 2008 end-page: 150 article-title: Cholangiocarcinoma publication-title: Clin Liver Dis – volume: 61 start-page: 1447 issue: 10 year: 2012 end-page: 1453 article-title: miR‐150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer publication-title: Gut – volume: 1 start-page: 21 issue: 1 year: 2011 end-page: 32 article-title: Cholangiocarcinoma: epidemiology and risk factors publication-title: Translational Gastrointestinal Cancer – volume: 6 start-page: 1265 issue: 5 year: 2013 end-page: 1270 article-title: miR‐31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1 publication-title: Exp Ther Med – volume: 24 start-page: 349 issue: 3 year: 2008 end-page: 356 article-title: Cholangiocarcinoma: lessons from Thailand publication-title: Curr Opin Gastroenterol – volume: 29 start-page: 221 issue: 2 year: 2015 end-page: 232 article-title: Epidemiology of cholangiocarcinoma publication-title: Best Pract Res Clin Gastroenterol – volume: 55 start-page: 111 issue: 4 year: 2011 end-page: 118 article-title: microRNAs as peripheral blood biomarkers of cardiovascular disease publication-title: Vascul Pharmacol – volume: 8 start-page: 80707 issue: 12 year: 2013 article-title: MiR‐150 promotes human breast cancer growth and malignant behavior by targeting the pro‐apoptotic purinergic P2X7 receptor publication-title: PLoS One – volume: 279 start-page: 2393 issue: 13 year: 2012 end-page: 2398 article-title: Down‐regulation of miR‐214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist publication-title: FEBS J – volume: 31 start-page: 7 issue: 1 year: 2000 end-page: 11 article-title: Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case‐control study publication-title: Hepatology – volume: 104 start-page: 48 issue: 1 year: 2013 end-page: 54 article-title: MiR‐150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1 publication-title: Cancer Sci – volume: 5 start-page: 132 issue: 7 year: 2013 end-page: 138 article-title: Risk factors and classifications of hilar cholangiocarcinoma publication-title: World J Gastrointest Oncol – volume: 50 start-page: 1734 issue: 9 year: 2005 end-page: 1740 article-title: The value of serum CA 19–9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis publication-title: Dig Dis Sci – volume: 49 start-page: 616 issue: 45 year: 2002 end-page: 620 article-title: The assessment of biliary CA 125, CA 19–9 and CEA in diagnosing cholangiocarcinoma–the influence of sampling time and hepatolithiasis publication-title: Hepatogastroenterology – volume: 9 start-page: 703 issue: 6 year: 2009 end-page: 711 article-title: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases publication-title: Expert Opin Biol Ther – volume: 24 start-page: 155 issue: 2 year: 2004 end-page: 164 article-title: Magnetic resonance imaging of cholangiocarcinoma publication-title: Semin Liver Dis – volume: 37 start-page: 15019 issue: 11 year: 2016 end-page: 15029 article-title: Profiling of downregulated blood‐circulating miR‐150‐5p as a novel tumor marker for cholangiocarcinoma publication-title: Tumor Biology – volume: 29 start-page: 245 issue: 2 year: 2015 end-page: 252 article-title: Clinical presentation, risk factors and staging systems of cholangiocarcinoma publication-title: Best Pract Res Clin Gastroenterol – volume: 51 start-page: 1 issue: 6 year: 2002 end-page: 9 article-title: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document publication-title: Gut – volume: 10 start-page: 704 issue: 10 year: 2009 end-page: 714 article-title: Causes and consequences of microRNA dysregulation in cancer publication-title: Nat Rev Genet – volume: 12 start-page: 1155 issue: 5 year: 2002 end-page: 1161 article-title: Multislice CT cholangiography without biliary contrast agent: technique and initial clinical results in the assessment of patients with biliary obstruction publication-title: Eur Radiol – volume: 283 start-page: 28274 issue: 42 year: 2008 end-page: 28286 article-title: MicroRNAs miR‐186 and miR‐150 down‐regulate expression of the pro‐apoptotic purinergic P2X7 receptor by activation of instability sites at the 3′‐untranslated region of the gene that decrease steady‐state levels of the transcript publication-title: J Biol Chem – volume: 12 start-page: 289 year: 2012 article-title: Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta‐analysis publication-title: BMC Cancer – volume: 50 start-page: 358 year: 2009 end-page: 369 article-title: The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma publication-title: J Hepatol – volume: 392 start-page: 340 issue: 3 year: 2010 end-page: 345 article-title: MiR‐150 promotes gastric cancer proliferation by negatively regulating the pro‐apoptotic gene EGR2 publication-title: Biochem Biophys Res Commun – volume: 9 start-page: 434 issue: 5 year: 2011 end-page: 439 article-title: Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19–9 do not have cholangiocarcinoma publication-title: Clin Gasteroenterol Hepatol – volume: 56 start-page: 1792 year: 2012 end-page: 1803 article-title: Transcriptomic profiling reveals hepatic stem‐like gene signatures and interplay of miR‐200c and epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma publication-title: Hepatology – volume: 6 start-page: 30 issue: 6 year: 2000 end-page: 34 article-title: Early detection and treatment of cholangiocarcinoma publication-title: Liver Transpl – volume: 6 start-page: 590 issue: 6 year: 2012 end-page: 610 article-title: MicroRNA and cancer publication-title: Molecular Oncology – volume: 14 start-page: 333 issue: 2 year: 2010 end-page: 348 article-title: Endoscopic retrograde cholangiopancreatography in the diagnosis and management of cholangiocarcinoma publication-title: Clin Liver Dis – volume: 33 start-page: 819 issue: 2 year: 2015 end-page: 825 article-title: Upregulated circulating miR‐150 is associated with the risk of intrahepatic cholangiocarcinoma publication-title: Oncol Rep – volume: 40 start-page: 43 issue: 1 year: 2008 end-page: 50 article-title: Widespread microRNA repression by Myc contributes to tumorigenesis publication-title: Nat Genet – volume: 5 start-page: 13515 year: 2010 article-title: Selective release of microRNA species from normal and malignant mammaryepithelial cells publication-title: PLoS One – volume: 8 start-page: 512 issue: 9 year: 2011 end-page: 522 article-title: Clinical diagnosis and staging of cholangiocarcinoma publication-title: Nat Rev Gastroenterol Hepatol – volume: 25 start-page: 126 issue: 2 year: 2008 end-page: 132 article-title: Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24‐year experience publication-title: Dig Surg – volume: 32 start-page: 1832 issue: 12 year: 2011 end-page: 1839 article-title: MicroRNA‐150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells publication-title: Carcinogenesis – volume: 23 start-page: 123 issue: 2 year: 2007 end-page: 135 article-title: The role of sonography in imaging of the biliary tract publication-title: Ultrasound Q – volume: 10 start-page: 11 year: 2015 end-page: 16 article-title: Role of microRNA‐150 in solid tumors publication-title: Oncol Lett – volume: 17 start-page: 1015 issue: 9 year: 2002 end-page: 1020 article-title: What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? publication-title: J Gastroenterol Hepatol – volume: 8 start-page: 158 year: 2013 article-title: Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray publication-title: Diagn Pathol – volume: 50 start-page: 1013 issue: 5 year: 2014 end-page: 1024 article-title: MiR‐150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signaling inhibitor 1 publication-title: Eur J Cancer – volume: 10 start-page: 427 issue: 3 year: 2004 end-page: 432 article-title: Utility of serum CA19‐9 in diagnosis of cholangiocarcinoma: in comparison with CEA publication-title: World J Gastroenterol – volume: 45 start-page: 54 issue: 1 year: 1999 end-page: 61 article-title: Reference values and biological variation for tumor marker CA 19–9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population publication-title: Clin Chem – volume: 24 start-page: 139 issue: 2 year: 2004 end-page: 154 article-title: Serum and bile markers for cholangiocarcinoma publication-title: Semin Liver Dis – ident: e_1_2_11_17_1 doi: 10.1055/s-2004-828891 – ident: e_1_2_11_4_1 doi: 10.1097/MOG.0b013e3282fbf9b3 – ident: e_1_2_11_5_1 doi: 10.1038/nrgastro.2011.131 – ident: e_1_2_11_45_1 doi: 10.1007/s10620-005-2927-8 – ident: e_1_2_11_25_1 doi: 10.1371/journal.pone.0080707 – volume: 49 start-page: 616 issue: 45 year: 2002 ident: e_1_2_11_15_1 article-title: The assessment of biliary CA 125, CA 19–9 and CEA in diagnosing cholangiocarcinoma–the influence of sampling time and hepatolithiasis publication-title: Hepatogastroenterology – ident: e_1_2_11_30_1 doi: 10.1136/gutjnl-2011-301122 – ident: e_1_2_11_32_1 doi: 10.1007/s13277-016-5313-6 – ident: e_1_2_11_39_1 doi: 10.1038/nrg2634 – ident: e_1_2_11_20_1 doi: 10.1517/14712590902932889 – ident: e_1_2_11_38_1 doi: 10.1074/jbc.M802663200 – ident: e_1_2_11_22_1 doi: 10.1186/1746-1596-8-158 – ident: e_1_2_11_21_1 doi: 10.1016/j.vph.2011.08.001 – ident: e_1_2_11_37_1 doi: 10.1002/hep.25890 – ident: e_1_2_11_11_1 doi: 10.1007/s00330-001-1188-y – ident: e_1_2_11_27_1 doi: 10.1016/j.bbrc.2009.12.182 – ident: e_1_2_11_24_1 doi: 10.3892/ol.2015.3170 – ident: e_1_2_11_44_1 doi: 10.1002/hep.510310103 – ident: e_1_2_11_43_1 doi: 10.1371/journal.pone.0013515 – ident: e_1_2_11_7_1 doi: 10.1186/1471-2407-12-289 – ident: e_1_2_11_10_1 doi: 10.1097/01.ruq.0000263851.53549.a5 – ident: e_1_2_11_12_1 doi: 10.1055/s-2004-828892 – volume: 45 start-page: 54 issue: 1 year: 1999 ident: e_1_2_11_16_1 article-title: Reference values and biological variation for tumor marker CA 19–9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population publication-title: Clin Chem – ident: e_1_2_11_6_1 doi: 10.1159/000128169 – ident: e_1_2_11_34_1 doi: 10.1016/j.cld.2007.11.003 – ident: e_1_2_11_23_1 doi: 10.1016/j.jhep.2008.09.015 – ident: e_1_2_11_19_1 doi: 10.1016/j.molonc.2012.09.006 – ident: e_1_2_11_29_1 doi: 10.1111/cas.12030 – ident: e_1_2_11_8_1 doi: 10.1046/j.1440-1746.2002.02779.x – ident: e_1_2_11_41_1 doi: 10.3748/wjg.v10.i3.427 – ident: e_1_2_11_2_1 doi: 10.1016/j.bpg.2015.02.003 – ident: e_1_2_11_36_1 doi: 10.1111/j.1742-4658.2012.08618.x – ident: e_1_2_11_9_1 doi: 10.1136/gut.51.suppl_6.vi1 – volume: 1 start-page: 21 issue: 1 year: 2011 ident: e_1_2_11_33_1 article-title: Cholangiocarcinoma: epidemiology and risk factors publication-title: Translational Gastrointestinal Cancer – ident: e_1_2_11_40_1 doi: 10.4251/wjgo.v5.i7.132 – ident: e_1_2_11_35_1 doi: 10.3892/etm.2013.1311 – ident: e_1_2_11_13_1 doi: 10.1053/jlts.2000.18688 – ident: e_1_2_11_26_1 doi: 10.1016/j.ejca.2013.12.024 – ident: e_1_2_11_28_1 doi: 10.1093/carcin/bgr223 – ident: e_1_2_11_42_1 doi: 10.1038/ng.2007.30 – ident: e_1_2_11_31_1 doi: 10.3892/or.2014.3641 – ident: e_1_2_11_18_1 doi: 10.1016/j.cgh.2011.02.007 – ident: e_1_2_11_14_1 doi: 10.1016/j.cld.2010.03.011 – ident: e_1_2_11_3_1 doi: 10.1016/j.bpg.2015.02.001 |
| SSID | ssj0008916 |
| Score | 2.373678 |
| Snippet | Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19‐9 (CA19‐9) is currently the most... Cholangiocarcinoma (CCA) is a rare tumor which requires a multimodality approach for its diagnosis. Carbohydrate antigen 19-9 (CA19-9) is currently the most... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e23397 |
| SubjectTerms | Abdomen Age Antigens Biomarkers Cell cycle Cholangiocarcinoma Cholangitis Colorectal cancer Diagnosis diagnosis of CCA Laboratories MicroRNAs miRNA Patients Phenols risk factors for CCA serum CA19‐9 serum MiRNA‐150 Tomography Tumor markers Tumorigenesis Tumors |
| SummonAdditionalLinks | – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fSxwxEB-qBfFFbKt2WysR-6Kw6m12k9yTHIci0rNQFHxbZpOcnlz39NT3foR-Rj-JM7ncnqL4tpAQNjOZmd8k8wfgJ7b62ktpU4K3nhwUpVik8lQjkj1TkhAH30P2TtXxeX5yUVzEC7e7GFY51YlBUbuR5TvyPa571i447vzg5jblrlH8uhpbaMzBR84BZefLdGchHqYdWp8GQSJNLJvypNnetR3ibiYlF3t6bpBeoczXwZLPQWywQkfLsBTho-hM-P0JPvj6Myz04gP5F_hNbBc4I7mIcVjCDsY2dOqqL0WPg_D-nHYe__0noCaGHDcksHYiOLr15YDs25jWG_3FFTg_OjzrHqexZ0JqizzTaX_fZ1VeOYsFYWeD1pMy85nCfZu5Qmtyr_raVmgVZx8YWXFyKTnIKF3LOLJnqzBfj2r_FYSyXitV0Hzjc6fQ6NxViCj7vuUIaCSwPSVcaWNBce5rMSwnpZCzkolcBiInsNXMvZmU0Xhz1vqU_mUUpbtyxvi3hxWn7rJPncBmM0wywg8fWPvRAy9RGFI0hH4SWJtws_kLKRnztk0C-gWfmwlcf_vlSD24CnW4teI7IFpzJ5yIdzZWnnR_dcLXt_e3-B0WM3boQ7LjOszfjx_8D0I999VGONpPXUj_1Q priority: 102 providerName: ProQuest |
| Title | The association between circulating MicroRNA‐150 level and cholangiocarcinoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcla.23397 https://www.ncbi.nlm.nih.gov/pubmed/33161598 https://www.proquest.com/docview/2461953514 https://www.proquest.com/docview/2606941322 https://www.proquest.com/docview/2458963081 https://pubmed.ncbi.nlm.nih.gov/PMC7676191 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VIiEuvB-GEi2CC0hOa6-9u5G4hNCqqkioIirlgqzxelPSBgelyYUTP4HfyC9hZu04hFZIcLEi7WZle-fxzXjmW4CXGI21k9KGBG8dBShKsUoloUYkf6YkIQ7OQ_YH6vAkORqloy14s-qFqfghmoQba4a316zgmF_srklDz-wU27Ekf0oGOJKKifPfDdfcUabjzz31WkRmWDbcpPHu-q-b3ugSxLxcKfk7gvUu6OA2fFrdfFV5ct5eLvK2_fYHr-P_Pt0duFVjU9GthOkubLnyHtzo11_f78MHkimB6_0UdZGXsJO59ceAlaeizxV-w0H35_cfhALFlIuSBJaF8FF0eToh5zmn9WZf8AGcHOx_7B2G9YEMoU2TWIfjPRfnSV5YTAmYG7SOLKWLFe7ZuEi1pthtrG2OVnFrg5E5d65S9I2yiExBzvIhbJez0j0GoazTSqU037ikUGh0UuSIKMcuKgjFBPBqtTGZrdnK-dCMaVbxLMcZv6HMv6EAXjRzv1YcHVfO2lntb1br6UXGbHqdlLsZrh5W3BfMAXsAz5thUkD-qoKlmy15idSQFSNoFcCjSlqau5CSAXXHBKA35KiZwOTemyPl5LMn-daKE0y05msvJn95sOyo977rfz35l8lP4WbMuQPfV7kD24v50j0jgLXIW3AtTo7pqkearqYXteD62_3B8bDlUxYtr2i_AG1rJq8 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fTxQxEJ_gkSgvxP8uoNaoD5qscO1uu_dAzImQA-5OQyDhbe22PThz7sEBMb75EfxEfhg_iTO97gKB8MbbJm2a7XSm85vp_AF4o5sD5YQwMcJbhwaKlCRSSay0Rn0mBSIO8kP2-rKzl2ztp_sz8LfKhaGwyupO9Be1HRvykS9T3bNWSnHnH4-OY-oaRa-rVQsNHVor2FVfYiwkdmy7Xz_RhDtZ3fyM5_2W84313bVOHLoMxCZNuIoHK44XSWGNThFtZto4FH_HpV4x3KZKoUEyUKbQRlK8fiYKSsdEk1IL28wsagBc9w7MJuRAacDsp_X-151aF2Qt33zVizLqAlEXSOXL381If-BCULmpiyrxCs69Gq55EUZ7PbhxH-YDgGXtKcc9gBlXPoS7vfBE_wi-IOMxfX7oLESCMTOcGN8rrDxgPQoD3Om3__3-g1CRjShyienSMm9qlwdD1LATXG_8Qz-GvVuh5xNolOPSPQMmjVNSpjg_c4mVOlOJLbTWYuCaFqFOBO8qwuUmlDSnzhqjfFqMmedE5NwTOYLX9dyjaSGPa2ctVfTPgzCf5Oesd_2wpORhsuojeFUPo5TS04su3fiMlkgzvOoQf0XwdHqa9V8IQai7lUWgLp1zPYEqgF8eKYeHvhK4kuSFwjXfe464YWP51lq37b8Wbt7iS7jX2e118-5mf3sR5ji5F3zq5RI0Tidn7jlisNPiRWB0Bt9uW7b-AxFqQm8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fTxQxEJ8gJsQXo4i6ilIDPGiy3l272-49GHIBL_y70xhJ7m3ptl08c-7hATG--RH8PH4cPokz3T9AILzxtkknzXY60_nNdDoDsKY7uXJCmBDhrUMHRUpSqShUWqM9kwIRB8UhB0O5fRDtjuLRHPyr38JQWmV9JvqD2k4NxchbVPesG1PeeSuv0iI-b_U3jn-G1EGKblrrdhqliOy537_QfTv5sLOFe73Oef_j183tsOowEJo44irM245nUWaNjhFpJto4VH3HpW4bbmOl0BnJlcm0kZSrn4iMnmKiO6mF7SQWT3-c9x7cVyKKqG2EGjXOXjvp-rarXonRCoimNCpvfTcT_Z4LQYWmLhvDawj3eqLmZQDtLWD_ETysoCvrlbL2GOZcsQgLg-py_gl8QpFj-mK7WZUDxsx4ZnyXsOKIDSgB8Muwd_7nL4JENqGcJaYLy7yTXRyN0bbOcL7pD70EB3fCzacwX0wL9xyYNE5JGSN94iIrdaIim2mtRe46FkFOAG9rxqWmKmZOPTUmaVmGmafE5NQzOYDVhva4LOFxI9Vyzf-0UuOT9ELobh6W9GyY_PkA3jTDqJ906aILNz2jKeIEDzlEXgE8K3ez-QshCG93kwDUlX1uCKj299WRYvzN1wBXkuJPOOc7LxG3LCzd3dzv-a8Xty9xBRZQo9L9neHeS3jAKa7g31wuw_zp7My9QvB1mr32Us7g8K7V6j9DiUAL |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+association+between+circulating+MicroRNA-150+level+and+cholangiocarcinoma&rft.jtitle=Journal+of+clinical+laboratory+analysis&rft.au=Salem%2C+Perihan+El+Sayed&rft.au=Ghazala%2C+Rasha+Abdelmawla&rft.au=El+Gendi%2C+Ahmed+Mohamed&rft.au=Emara%2C+Doaa+Mokhtar&rft.date=2020-11-01&rft.eissn=1098-2825&rft.volume=34&rft.issue=11&rft.spage=e23397&rft_id=info:doi/10.1002%2Fjcla.23397&rft_id=info%3Apmid%2F33161598&rft.externalDocID=33161598 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0887-8013&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0887-8013&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0887-8013&client=summon |